Kayne Richard A Sent A Letter To The Board Of Directors Of Athira Pharma, Inc.

My Fellow Shareholders:

As one of the largest shareholders in Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”), I believe in the Company’s long-term prospects and ATH-1017, a potentially game-changing treatment for Alzheimer’s disease. However, under Athira’s current Board of Directors (the “Board”) and management team, I fear that ATH-1017…